Is Thyroid Health a National Priority? Minister Pushes for Awareness and Research Partnerships
Synopsis
Key Takeaways
Mumbai, Feb 9 (NationPress) Union Minister Dr. Jitendra Singh emphasized on Monday that thyroid disorders present a significant national issue, intricately tied to productivity, demographics, and the overall development of the nation.
He called upon the Indian Thyroid Society and the broader medical community to enhance awareness, foster collaborative research, and prioritize early detection, as stated in an official release.
During a conference with endocrinologists, Dr. Singh noted that undiagnosed thyroid conditions, especially hypothyroidism, can diminish energy levels, reduce workforce efficiency, and ultimately impact the long-term productivity of a nation with over 70% of its population below 40 years of age.
With approximately 42 million Indians affected by thyroid disorders, Singh highlighted the need for a robust research focus and public health response to tackle this challenge effectively.
He advocated for enhanced multidisciplinary cooperation among life sciences, medical sciences, and related sectors to comprehensively address thyroid disorders. He insisted that such significant medical issues cannot be relegated to a single domain but require broader societal knowledge and institutional collaboration.
Hypothyroidism impacts nearly 11% of the adult population, and many cases go undiagnosed. Undetected hypothyroidism during pregnancy can lead to congenital hypothyroidism and irreversible neurodevelopmental damage in children.
Furthermore, the minister spotlighted the Biopharma Shakti Mission, India’s advances in biotechnology, and the establishment of the Anusandhan National Research Foundation, along with a Rs 1 lakh crore framework for Research Development and Innovation to bolster research through private and philanthropic involvement.
He referenced India’s advancements in biotechnology, such as the development of the nation’s first indigenously-produced antibiotic effective against resistant infections, successful gene therapy trials for haemophilia, and the deployment of the DNA vaccine during the COVID-19 pandemic.